Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients

This systematic review and network meta-analysis revealed that the use of low-molecular-weight heparin (LMWH) may be more effective than unfractionated heparin (UFH) in reducing incidence of deep vein thrombosis (DVT) among critically ill patients.

Benefit of Prophylaxis for High-Risk Surgical Patients

About Type 2 Inflammation – Nasal Polyps

Independent Risk Factors for Venous Thromboembolism

Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)

Many associated factors are modifiable indicating potential benefit from planned strategies.

Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery

Trends in Pulmonary Embolism-related mortality in Europe

An analysis of vital registration data from the WHO Mortality Database (2000-2015).

Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery

Guidelines recommend postoperative prophylactic anticoagulation for 1-5 weeks.

Sanofi Pasteur at Glance

Sanofi Pasteur at Glance

Maternity Clot Risk Model to Predict Women at Risk of VTE

How do you know if you or a loved one has ASMD?